Article Text

Download PDFPDF
Self-monitoring of oral anticoagulation reduces thromboembolic events and does not increase risk of bleeding in selected patients and settings
  1. Hanna Bloomfield
  1. Center for Chronic Disease Outcomes Research, VA Medical Center, Minneapolis, Minnesota, USA
  1. Correspondence to: Hanna Bloomfield
    VA Medical Center, 1 Veterans Drive (111-O), Minneapolis, MN 55417, USA; hanna.bloomfield{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Although oral anticoagulation with vitamin K antagonists reduces major thromboembolism in high-risk patients, it requires frequent laboratory monitoring to prevent over-anticoagulation which can result in serious bleeding or under anticoagulation which increases the risk for thromboembolism. This monitoring typically occurs in clinical settings, but with marketing of accurate and reliable portable devices, it can now be done more conveniently by the patient at home. Several clinical trials have evaluated the safety and efficacy of patient self-monitoring: either patient self-management (patient tests and adjusts the dose as needed) or patient self-testing with clinical dosing (dosing changes determined by clinicians). Heneghan …

View Full Text


  • Competing interests None.